COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES CONDITION OR PROCESSES CHARACTERIZED BY ABERRANT PROLIFERATION OF FIBROBLASTS AND DEPOSITION OF THE EXTRACELLULAR MATRIX
1. A pharmaceutical composition for use in the treatment of a disease, condition or pathological process characterized by aberrant fibroblast proliferation and deposition of an extracellular matrix in an individual's tissue, where the pharmaceutical composition contains a therapeutic amount of a YARAAARQARAKALARQLGVAA amino acid sequence polypeptide (SEQ ID NO: 1) or its functional equivalent and its functional equivalent a pharmaceutically acceptable carrier, also a therapeutic amount, is effective to reduce fibroblast proliferation and deposition of extra extracellular matrix in an individual's tissue. 2. The pharmaceutical composition of claim 1, wherein the disease or condition is acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The pharmaceutical composition of claim 1, wherein the disease or condition is fibrosis caused by radiation. The pharmaceutical composition of claim 1, wherein the disease or condition is transplant rejection. The pharmaceutical composition of claim 1, wherein the tissue is lung tissue. The pharmaceutical composition of claim 1, wherein the disease or condition is an interstitial pulmonary disease. The pharmaceutical composition of claim 1, wherein the disease or condition is pulmonary fibrosis. The pharmaceutical composition of claim 7, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis. The pharmaceutical composition of claim 7, wherein pulmonary fibrosis develops as a result of administration of bleomycin. The pharmaceutical composition according to claim 7, where pulmonary fibrosis develops as a result of an allergic reaction, inhalation of substances in the form of1. Фармацевтическая композиция для применения в лечении заболевания, состояния или патологического процесса, характеризуемого аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса в ткани индивида,где фармацевтическая композиция содержит терапевтическое количество полипептида аминокислотной последовательности YARAAARQ
